No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 38.54M | 220.18M | 270.26M | 423.24M |
| Revenue Growth % | - | - | - | - | - | - | 4.71% | 0.23% | 0.57% |
| Cost of Goods Sold | 22K | 28K | 286K | 3.28M | 3.81M | 9.1M | 22.89M | 56.52M | 60.91M |
| COGS % of Revenue | - | - | - | - | - | 0.24% | 0.1% | 0.21% | 0.14% |
| Gross Profit | -22K | -28K | -286K | -3.28M | -3.81M | 29.44M | 197.28M | 213.74M | 362.33M |
| Gross Margin % | - | - | - | - | - | 0.76% | 0.9% | 0.79% | 0.86% |
| Gross Profit Growth % | - | -0.27% | -9.21% | -10.47% | -0.16% | 8.74% | 5.7% | 0.08% | 0.7% |
| Operating Expenses | 24M | 65.4M | 108.16M | 166.68M | 153.56M | 186.08M | 187.51M | 238.93M | 407.94M |
| OpEx % of Revenue | - | - | - | - | - | 4.83% | 0.85% | 0.88% | 0.96% |
| Selling, General & Admin | 6.56M | 9.04M | 21.56M | 33.75M | 43.92M | 85.95M | 97.95M | 129.43M | 168.01M |
| SG&A % of Revenue | - | - | - | - | - | 2.23% | 0.44% | 0.48% | 0.4% |
| Research & Development | 17.44M | 56.36M | 86.6M | 132.93M | 109.64M | 99.3M | 65.49M | 76.1M | 111.62M |
| R&D % of Revenue | - | - | - | - | - | 2.58% | 0.3% | 0.28% | 0.26% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 835K | 24.07M | 33.41M | 128.31M |
| Operating Income | -24M | -65.4M | -108.16M | -169.96M | -157.36M | -156.64M | 9.77M | -25.2M | -45.62M |
| Operating Margin % | - | - | - | - | - | -4.06% | 0.04% | -0.09% | -0.11% |
| Operating Income Growth % | - | -1.72% | -0.65% | -0.57% | 0.07% | 0% | 1.06% | -3.58% | -0.81% |
| EBITDA | -23.98M | -65.37M | -107.87M | -166.68M | -153.56M | -154.28M | 12.18M | -22.86M | -43.92M |
| EBITDA Margin % | - | - | - | - | - | -4% | 0.06% | -0.08% | -0.1% |
| EBITDA Growth % | - | -1.73% | -0.65% | -0.55% | 0.08% | -0% | 1.08% | -2.88% | -0.92% |
| D&A (Non-Cash Add-back) | 22K | 28K | 286K | 3.28M | 3.81M | 2.35M | 2.4M | 2.34M | 1.7M |
| EBIT | -24M | -65.4M | -108.16M | -163.91M | -156.23M | -156.64M | 9.77M | -25.2M | -45.62M |
| Net Interest Income | 0 | 0 | 0 | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M |
| Interest Income | 65K | 529K | 4.72M | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 65K | 529K | 4.72M | 6.05M | 1.13M | 97K | 1.25M | 8.54M | 9.46M |
| Pretax Income | -23.94M | -64.87M | -103.44M | -163.91M | -156.23M | -156.54M | 11.03M | -16.65M | -36.15M |
| Pretax Margin % | - | - | - | - | - | -4.06% | 0.05% | -0.06% | -0.09% |
| Income Tax | 36K | 2K | -214K | -2.05M | 5.15M | 1.39M | -172.34M | -30.74M | 7.04M |
| Effective Tax Rate % | 1% | 1% | 1% | 0.99% | 1.03% | 1.01% | 16.63% | -0.85% | 1.19% |
| Net Income | -23.97M | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M |
| Net Margin % | - | - | - | - | - | -4.1% | 0.83% | 0.05% | -0.1% |
| Net Income Growth % | - | -1.71% | -0.59% | -0.57% | 0% | 0.02% | 2.16% | -0.92% | -4.07% |
| Net Income (Continuing) | -23.97M | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.74 | -2.00 | -3.49 | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 |
| EPS Growth % | - | -1.7% | -0.74% | 0.14% | 0.13% | 0.12% | 2.13% | -0.92% | -4% |
| EPS (Basic) | -0.74 | -2.00 | -3.49 | -2.99 | -2.61 | -2.30 | 2.64 | 0.20 | -0.60 |
| Diluted Shares Outstanding | 32.47M | 32.47M | 29.55M | 54.05M | 61.84M | 68.58M | 70.42M | 71.92M | 71.42M |
| Basic Shares Outstanding | 32.47M | 32.47M | 29.55M | 54.05M | 61.84M | 68.58M | 69.38M | 70.06M | 71.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 56.33M | 47.1M | 313.75M | 241.63M | 333.25M | 196.45M | 243.06M | 276.3M | 331.8M |
| Cash & Short-Term Investments | 55.97M | 45.55M | 307.3M | 233.38M | 323.48M | 182.2M | 190.61M | 206.37M | 243.63M |
| Cash Only | 55.97M | 45.55M | 307.3M | 46.93M | 114.04M | 122.47M | 122.72M | 107.95M | 183.58M |
| Short-Term Investments | 0 | 0 | 0 | 186.45M | 209.44M | 59.73M | 67.89M | 98.42M | 60.05M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 3.98M | 20.32M | 21.27M | 41.72M |
| Days Sales Outstanding | - | - | - | - | - | 37.74 | 33.68 | 28.72 | 35.98 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.67M | 21.6M | 31.12M | 26.36M |
| Days Inventory Outstanding | - | - | - | - | - | 147.4 | 344.34 | 200.97 | 157.98 |
| Other Current Assets | 105K | 105K | 6.45M | 0 | 210K | 0 | 10.54M | 17.54M | 20.08M |
| Total Non-Current Assets | 133K | 388K | 8.21M | 12.91M | 16.21M | 36.35M | 216.61M | 250.03M | 248.75M |
| Property, Plant & Equipment | 84K | 125K | 6.36M | 8.32M | 10.62M | 8.38M | 7.04M | 12.66M | 11.04M |
| Fixed Asset Turnover | - | - | - | - | - | 4.60x | 31.26x | 21.34x | 38.34x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 19.25M | 18.25M | 17.25M | 16.25M |
| Long-Term Investments | 0 | 0 | 210K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 8K | 25K | 643K | 210K | 5.59M | 8.72M | 5.82M | 827K | 10.31M |
| Total Assets | 56.47M | 47.49M | 321.96M | 254.53M | 349.46M | 232.8M | 459.67M | 526.32M | 580.55M |
| Asset Turnover | - | - | - | - | - | 0.17x | 0.48x | 0.51x | 0.73x |
| Asset Growth % | - | -0.16% | 5.78% | -0.21% | 0.37% | -0.33% | 0.97% | 0.14% | 0.1% |
| Total Current Liabilities | 2.3M | 17.43M | 42.55M | 27.83M | 31.85M | 44.82M | 47.07M | 63.67M | 100.62M |
| Accounts Payable | 212K | 1.22M | 10.92M | 5.69M | 503K | 1.87M | 7.9M | 8.25M | 2.04M |
| Days Payables Outstanding | 3.52K | 15.88K | 13.93K | 633.71 | 48.25 | 74.93 | 125.93 | 53.25 | 12.22 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 307K | 0 |
| Other Current Liabilities | 1.1M | 14.64M | 25.96M | 7.11M | 7.74M | 1.54M | 16.97M | 36.91M | 96.59M |
| Current Ratio | 24.47x | 2.70x | 7.37x | 8.68x | 10.46x | 4.38x | 5.16x | 4.34x | 3.30x |
| Quick Ratio | 24.47x | 2.70x | 7.37x | 8.68x | 10.46x | 4.30x | 4.71x | 3.85x | 3.04x |
| Cash Conversion Cycle | - | - | - | - | - | 110.22 | 252.09 | 176.44 | 181.75 |
| Total Non-Current Liabilities | 79.9M | 119.77M | 144K | 1.28M | 5.68M | 2.94M | 16.46M | 23.82M | 41.5M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 955K | 4.88M | 2.67M | 2.62M | 10.01M | 7.86M |
| Deferred Tax Liabilities | 0 | 0 | 1.22M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 79.9M | 119.77M | 144K | 326K | 805K | 270K | 1.84M | 1.86M | 1.82M |
| Total Liabilities | 82.2M | 137.2M | 42.7M | 29.11M | 37.53M | 47.76M | 63.52M | 87.48M | 142.12M |
| Total Debt | 0 | 0 | 0 | 2.65M | 6.99M | 6.05M | 5.92M | 12.26M | 9.86M |
| Net Debt | -55.97M | -45.55M | -307.3M | -44.28M | -107.05M | -116.42M | -116.8M | -95.7M | -173.73M |
| Debt / Equity | - | - | - | 0.01x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | 0.49x | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | -9.59x | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | -25.73M | -89.71M | -194.22M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M |
| Equity Growth % | - | -2.49% | -1.17% | 2.16% | 0.38% | -0.41% | 1.14% | 0.11% | -0% |
| Book Value per Share | -0.79 | -2.76 | -6.57 | 4.17 | 5.04 | 2.70 | 5.63 | 6.10 | 6.14 |
| Total Shareholders' Equity | -25.73M | -89.71M | -194.22M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M |
| Common Stock | 1K | 1K | 13K | 15K | 18K | 18K | 19K | 20K | 20K |
| Retained Earnings | -26.13M | -91M | -194.22M | -356.09M | -517.47M | -675.4M | -492.03M | -477.95M | -521.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -24K | -52K | -4K | 33K | -34K | -66K | 44K | 6K | -163K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -21.87M | -50.22M | -81.01M | -158.37M | -136.53M | -126.3M | 5.81M | 13.3M | 25.69M |
| Operating CF Margin % | - | - | - | - | - | -3.28% | 0.03% | 0.05% | 0.06% |
| Operating CF Growth % | - | -1.3% | -0.61% | -0.95% | 0.14% | 0.07% | 1.05% | 1.29% | 0.93% |
| Net Income | -23.97M | -64.87M | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M |
| Depreciation & Amortization | 22K | 28K | 286K | 2.07M | 2.4M | 2.35M | 2.4M | 2.34M | 1.7M |
| Stock-Based Compensation | 368K | 897K | 5.7M | 15.08M | 20.88M | 25.17M | 25.12M | 27.15M | 30.69M |
| Deferred Taxes | -46K | -197K | -978K | -3.16M | 4.36M | 11K | -185.5M | -33.79M | 8.13M |
| Other Non-Cash Items | 293K | -53K | -1.12M | 6.53M | 1.52M | 3.4M | 2.99M | 2.17M | 3.55M |
| Working Capital Changes | 1.76M | 13.93M | 18.33M | -17.02M | -4.32M | 689K | -22.57M | 1.35M | 24.81M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -3.91M | -16.33M | -950K | -20.46M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.67M | -17.92M | -9.52M | 4.76M |
| Change in Payables | 119K | 1.01M | 8.82M | -4.71M | -4.97M | 1.37M | 6.03M | 347K | -6.31M |
| Cash from Investing | -3K | -69K | -239.2M | 49.21M | -23.44M | 128.63M | -8.08M | -29.56M | 37.67M |
| Capital Expenditures | -3K | -69K | -5.29M | -3.2M | -283K | -415K | -105K | -130K | -277K |
| CapEx % of Revenue | - | - | - | - | - | 0.01% | 0% | 0% | 0% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -233.91M | 52.42M | -23.16M | -20M | 91K | 0 | 0 |
| Cash from Financing | 42.51M | 39.87M | 346.74M | 84.11M | 227.09M | 5.88M | 2.52M | 1.5M | 12.27M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 10K | 0 | -3.28M | 1M | -1.14M | 5.88M | -901K | 3.7M | 17.25M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -21.87M | -50.29M | -86.3M | -161.57M | -136.81M | -146.71M | 5.7M | 13.17M | 25.41M |
| FCF Margin % | - | - | - | - | - | -3.81% | 0.03% | 0.05% | 0.06% |
| FCF Growth % | - | -1.3% | -0.72% | -0.87% | 0.15% | -0.07% | 1.04% | 1.31% | 0.93% |
| FCF per Share | -0.67 | -1.55 | -2.92 | -2.99 | -2.21 | -2.14 | 0.08 | 0.18 | 0.36 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.77x | 0.78x | 0.98x | 0.85x | 0.80x | 0.03x | 0.94x | -0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 115K | 290K | 383K | 1.72M | 482K | 1.28M | 10.69M | 5.61M | 2M |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -1037.68% | -60.06% | -63.55% | 63.1% | 3.37% | -9.85% |
| Return on Invested Capital (ROIC) | - | - | - | -70.37% | -61.15% | -85.91% | 4.21% | -6.07% | -11.26% |
| Gross Margin | - | - | - | - | - | 76.39% | 89.6% | 79.09% | 85.61% |
| Net Margin | - | - | - | - | - | -409.72% | 83.28% | 5.21% | -10.21% |
| Debt / Equity | - | - | - | 0.01x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x |
| FCF Conversion | 0.91x | 0.77x | 0.78x | 0.98x | 0.85x | 0.80x | 0.03x | 0.94x | -0.59x |
| Revenue Growth | - | - | - | - | - | - | 471.24% | 22.74% | 56.61% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Product | 122.52M | 233.18M | 417.03M |
| Product Growth | - | 90.31% | 78.85% |
| Collaboration | 97.66M | 37.08M | 6.21M |
| Collaboration Growth | - | -62.03% | -83.25% |
Kiniksa Pharmaceuticals, Ltd. (KNSA) reported $598.0M in revenue for fiscal year 2024.
Kiniksa Pharmaceuticals, Ltd. (KNSA) grew revenue by 56.6% over the past year. This is strong growth.
Yes, Kiniksa Pharmaceuticals, Ltd. (KNSA) is profitable, generating $35.9M in net income for fiscal year 2024 (-10.2% net margin).
Kiniksa Pharmaceuticals, Ltd. (KNSA) has a return on equity (ROE) of -9.8%. Negative ROE indicates the company is unprofitable.
Kiniksa Pharmaceuticals, Ltd. (KNSA) generated $101.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.